Literature DB >> 11464905

Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?

J Vandesompele1, F Speleman, N Van Roy, G Laureys, C Brinskchmidt, H Christiansen, F Lampert, M Lastowska, N Bown, A Pearson, J C Nicholson, F Ross, V Combaret, O Delattre, B G Feuerstein, D Plantaz.   

Abstract

PROCEDURE: Analysis of comparative genomic hybridization (CGH) data of 120 tumors from four different studies, and data of 84 previously unpublishied tumors, allowed delineation of at least six different genetic subsets of neuroblastomas. RESULTS AND
CONCLUSIONS: A small number of tumors show no detectable imballances. A second group of tumors presents with gains and losses of whole chromosomes and is found predominantly in prognostically favorable stage 1 and 2 tumors. The remaining groups are characterized by the presence of partial chromosome imbalances, and are found mostly in stage 3, 4, and 4S tumors. The third group shows 17q gain without 11q loss, 1p loss, or MYCN amplification (MNA). The fourth group has 1p deletion or MNA, and finally, a fifth group shows 11q loss without 1p deletion or MNA, and is found mainly in stage 4 tumors. The latter group is significantly associated with losses of 3p, 4p, and 14q.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11464905     DOI: 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  26 in total

1.  Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups.

Authors:  Sara Dyer; Emma Prebble; Val Davison; Paul Davies; Pramila Ramani; David Ellison; Richard Grundy
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.

Authors:  Jan J Molenaar; Jan Koster; Danny A Zwijnenburg; Peter van Sluis; Linda J Valentijn; Ida van der Ploeg; Mohamed Hamdi; Johan van Nes; Bart A Westerman; Jennemiek van Arkel; Marli E Ebus; Franciska Haneveld; Arjan Lakeman; Linda Schild; Piet Molenaar; Peter Stroeken; Max M van Noesel; Ingrid Ora; Evan E Santo; Huib N Caron; Ellen M Westerhout; Rogier Versteeg
Journal:  Nature       Date:  2012-02-22       Impact factor: 49.962

3.  Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.

Authors:  Setsuko Kaneko; Miki Ohira; Yohko Nakamura; Eriko Isogai; Akira Nakagawara; Michio Kaneko
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-07       Impact factor: 4.553

Review 4.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

5.  High genomic instability predicts survival in metastatic high-risk neuroblastoma.

Authors:  Sara Stigliani; Simona Coco; Stefano Moretti; Andrè Oberthuer; Mattias Fischer; Jessica Theissen; Fabio Gallo; Alberto Garavent; Frank Berthold; Stefano Bonassi; Gian Paolo Tonini; Paola Scaruffi
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

6.  Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.

Authors:  John M Maris; George Hii; Craig A Gelfand; Shobha Varde; Peter S White; Eric Rappaport; Saul Surrey; Paolo Fortina
Journal:  Genome Res       Date:  2005-08       Impact factor: 9.043

7.  Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification.

Authors:  Sven Bilke; Qing-Rong Chen; Jun S Wei; Javed Khan
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

8.  Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade.

Authors:  Audrey Rousseau; Ahmed Idbaih; François Ducray; Emmanuelle Crinière; Michèle Fèvre-Montange; Anne Jouvet; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2009-10-29       Impact factor: 4.130

9.  NFκB-inducing kinase inhibits NFκB activity specifically in neurons of the CNS.

Authors:  Xianrong Mao; Bounleut Phanavanh; Hamdan Hamdan; Andréa M Moerman-Herzog; Steven W Barger
Journal:  J Neurochem       Date:  2016-03-15       Impact factor: 5.372

10.  The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Authors:  Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman
Journal:  Genome Med       Date:  2009-07-27       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.